Anthem Biosciences

About the Company

Anthem Biosciences, established in 2006, is an innovation-driven Contract Research, Development, and Manufacturing Organisation (CRDMO) that offers integrated services in drug discovery, development, and manufacturing. The company specialises in fermentation-based APIs, including probiotics, enzymes, peptides, and biosimilars, catering to both biotech startups and large pharma worldwide. With 196 active projects, including 170 discovery projects, Anthem’s R&D spans RNAi, ADCs, and peptides. The company’s manufacturing facilities, including one under construction, support a broad portfolio of custom synthesis and fermentation capabilities. Known for green chemistry and cutting-edge technologies, Anthem is a leader in delivering sustainable, high-quality solutions across regulated markets.

Strengths

• Comprehensive services across the drug life cycle for small molecules and biologics
• Focus on advanced solutions across modalities and manufacturing practices
• Specialised model for small pharmaceutical and biotech companies
• Established customer base with ongoing relationships
• Experienced leadership and skilled scientific team

Risks

• Failure to develop new or improve existing technologies.
• Delays in obtaining regulatory approvals.
• Under-utilisation of manufacturing capacity and demand forecasting issues.
• Pricing pressures affecting product prices and profitability.
• Risks from data security breaches and failure to safeguard sensitive information.
• Seasonality affecting business performance and cash flow.